Biblio Discovery — Demo Discovery Service

4 hasil untuk "Probst, Jochen"

Menampilkan 1–4 · 0,22 detik · RSS

  1. Artikel Jurnal Teks lengkap

    Characterization of the ribonuclease activity on the skin surface

    Probst, Jochen; Brechtel, Sonja; Scheel, Birgit dkk.

    Genet Vaccines Ther · 2006 · Inggris · PubMed Central

    The rapid degradation of ribonucleic acids (RNA) by ubiquitous ribonucleases limits the efficacy of new therapies based on RNA molecules. Therefore, our aim was to characterize the natural ribonuclease activities on the skin and in blood plasma i.e. at sites where many drugs in development are…

  2. Artikel Jurnal Teks lengkap

    Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas

    Carralot, Jean-Philippe; Weide, Benjamin; Schoor, Oliver dkk.

    Genet Vaccines Ther · 2005 · Inggris · PubMed Central

    BACKGROUND: Anti-tumor vaccines targeting the entire tumor antigen repertoire represent an attractive immunotherapeutic approach. In the context of a phase I/II clinical trial, we vaccinated metastatic melanoma patients with autologous amplified tumor mRNA. In order to provide the large quantities…

  3. Artikel Jurnal Teks lengkap

    Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study

    Kübler, Hubert; Scheel, Birgit; Gnad-Vogt, Ulrike dkk.

    J Immunother Cancer · 2015 · Inggris · PubMed Central

    BACKGROUND: CV9103 is a prostate-cancer vaccine containing self-adjuvanted mRNA (RNActive®) encoding the antigens PSA, PSCA, PSMA, and STEAP1. This phase I/IIa study evaluated safety and immunogenicity of CV9103 in patients with advanced castration-resistant prostate-cancer. METHODS: 44 Patients…

  4. Artikel Jurnal Teks lengkap

    A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer

    Sebastian, Martin; Schröder, Andreas; Scheel, Birgit dkk.

    Cancer Immunol Immunother · 2019 · Inggris · PubMed Central

    CV9201 is an RNActive(®)-based cancer immunotherapy encoding five non-small cell lung cancer-antigens: New York esophageal squamous cell carcinoma-1, melanoma antigen family C1/C2, survivin, and trophoblast glycoprotein. In a phase I/IIa dose-escalation trial, 46 patients with locally advanced (n =…